Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
Lecanemab, an experimental Alzheimer's drug, shows potential in slowing cognitive decline by 27% in Phase 3 trials, despite safety concerns. It reduces amyloid levels and cognitive decline more than placebo at 18 months but is associated with adverse events like brain swelling and bleeding. Longer trials are needed to confirm its efficacy and safety.
Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment
Integrin αvβ6 plays a crucial role in cell adhesion, migration, and signaling, with significant implications in cancer progression and epithelial-mesenchymal transition (EMT). Its up-regulation is linked to poor prognosis in various cancers, making it a potential target for cancer treatment. Research focuses on its biology, role in healthy humans, and therapeutic targeting strategies, including imaging and drug delivery approaches.
Related Clinical Trials:
Alzheimer’s Drug Slows Cognitive Decline in Key Study
Biogen and Eisai's Alzheimer's drug, lecanemab, showed a 27% reduction in cognitive decline in a large trial, offering hope after previous failures. This marks a potential turnaround for Biogen, following the commercial failure of Aduhelm.
Alzheimer's-slowing drug labelled historic
Lecanemab, a drug by Eisai and Biogen, slows Alzheimer's progression by 27% in early stages, targeting toxic beta-amyloid proteins. Despite side effects like brain swelling, it's hailed as a historic breakthrough, offering hope for meaningful cognitive impact. Full trial details await, with regulatory approval sought in the US, Europe, and Japan.
Covalent Modifiers: Advancements in Drug Discovery for Oncology and Beyond
The article highlights advancements in covalent drug discovery, focusing on inhibitors targeting KEAP1/NRF2, KRAS(G12C), WRN helicase, and other oncology targets. It discusses novel compounds like BBO-8520, RMC-9805, VVD-214, and PF-07817883, emphasizing their mechanisms, clinical trials, and potential in treating cancers and COVID-19. The piece also covers the evolution of covalent inhibitors beyond oncology, showcasing significant approvals and acquisitions.
The FDA approves many drugs that haven’t been shown to work
FDA's accelerated approval process allows drugs like Makena to market without proven effectiveness, risking patient safety. Despite required follow-up studies, many drugs remain unverified, with companies delaying research. Critics argue this process exploits patients, offering expensive treatments of questionable benefit.
Biotechs face cash crunch after stock market 'bloodbath'
Biotech companies face cash shortages as 'tourist' investors exit, with 83% of recent US biotech IPOs trading below their offering price. The sector's downturn, exacerbated by inflation concerns and regulatory scrutiny, has led to a dramatic valuation drop, forcing companies to seek alternative funding and consider cost-cutting measures.
Global Peptide Cancer Drug Therapeutics Market Clinical Analysis and Forecast
The global peptide cancer therapeutics market is projected to exceed US$ 20 billion by 2026, driven by the increasing prevalence of cancer and the demand for efficient treatments. Over 150 cancer peptides are in clinical trials, with more than 20 already marketed. Peptides offer advantages like high tissue permeability and the ability to cross the blood-brain barrier, making them effective in cancer management. Major pharmaceutical companies are investing in peptide-based drugs, with strategic alliances and new product launches fueling market growth.
On the hunt for new ALS drugs, researchers see progress
ALS, a fatal neurodegenerative disease, has seen limited treatment options despite its discovery over a century ago. Recent scientific advancements offer hope, with new drugs like AMX0035 showing modest benefits in slowing disease progression and extending survival. However, challenges remain in understanding ALS's biology and developing effective treatments, especially for sporadic cases without known causes. The field is witnessing increased investment and research, aiming for breakthroughs that could significantly improve patients' lives.
3 Experts Quit An FDA Panel Over Alzheimer's Drug Approval
Three FDA advisory committee experts resigned after Aduhelm's controversial approval for Alzheimer's, citing insufficient proof of efficacy and potential negative precedents for future drug evaluations. The drug's high cost and mixed study results add to the debate, with some celebrating the approval as a step forward for patient advocacy.
© Copyright 2025. All Rights Reserved by MedPath